Protomer
Pasadena, US · 1 known investors
Protomer engineers responsive biotherapeutics that sense molecular activators in the body using its proprietary Molecular Evolution of Peptide Sensors (MEPS) platform. The company develops therapeutic peptides and proteins with tunable activity, including glucose-responsive insulin receptor agonists for diabetes treatment.